#USA #Princeton #Cell Therapy #Made Scientific #CARR Biosystems

Innovative Partnership in Cell Therapy

In a significant development in the field of biotechnology, Made Scientific, Inc. has announced its strategic partnership with CARR Biosystems, a leader in cell processing technologies. This collaboration aims to enhance the manufacturing process for allogeneic cell therapies—a groundbreaking approach that could reshape how these treatments are produced at scale.

About the Partnership

Announced on October 26, 2026, this partnership will see Made Scientific integrate multiple UniFuge® single-use centrifugation systems across its facilities located in Princeton, New Jersey, and East Norriton, Pennsylvania. The addition of CARR's technology is expected to bolster the efficiency of Made Scientific's production of mesenchymal stem cells (MSCs) and feeder cells, particularly in large-scale manufacturing operations.

Syed T. Husain, Chairman and CEO of Made Scientific, emphasized the importance of scaling all components of the cell therapy process. "Allogeneic therapies reach patients at commercial scale only when the whole process scales, not just the bioreactor," he noted. By addressing potential bottlenecks during the harvest and wash stages, the partnership aims to ensure optimal yields in cell manufacturing.

How the UniFuge Technology Works

The UniFuge technology is designed to maintain high cell viability and product recovery while providing automated operations. It allows for a seamless transition through various process volumes, supporting applications ranging from small-scale development to commercial production that exceeds 2,000 liters. This feature allows Made Scientific to effectively manage its processes as it transitions from clinical studies to commercial readiness.

Enhancing Manufacturing Capabilities

Made Scientific plans to utilize the UniFuge systems alongside its robust 3D bioreactor platforms, which can accommodate volumes of up to 200 liters. This integration promises not only efficient cell harvesting and washing but also a more consistent approach to production as it scales up. Sponsors will experience a more straightforward journey from early-phase manufacturing to commercial supply, as the technologies employed at smaller scales can easily be translated to larger volumes.

As both companies embark on joint development studies, they will utilize CARR's benchtop UFMini® system to gather data that informs scaling to larger volumes—all while ensuring a direct path to commercial readiness for their customers.

Broader Impact on Cell Therapy

The partnership is not just about enhancing existing processes; it's a strategic move aimed at addressing the growing demand for scalable and reliable manufacturing solutions in the cell therapy industry. Made Scientific's expanded operational capabilities are complemented by its collaboration with RoosterBio, a notable player in human MSCs and engineering media.

This partnership enables seamless technology transfer and bridges the gap between research and manufacturing, providing sponsors with a comprehensive pathway for their therapeutic programs.

Joel Williams, President of CARR Biosystems, highlighted how Made Scientific's clinical-to-commercial capabilities align perfectly with the design philosophy of the UniFuge platform. Their combined expertise is anticipated to increase the confidence of cell therapy developers as they transition processes from the clinic to larger-scale production.

Looking Ahead

With acquiring operational GMP facilities and ongoing enhancements in their technology infrastructure, Made Scientific is poised to meet the surging demand for cell therapy manufacturing. The collaboration with CARR Biosystems positions them as a leading contract development and manufacturing organization (CDMO) in the industry, essential for advancing the efficiency of cell therapies that hold promise for countless patients.

In conclusion, the partnership between Made Scientific and CARR Biosystems marks a vital step forward in the field of biotechnology. It demonstrates the importance of integrating advanced technologies into manufacturing processes to propel the future of cell therapies, ultimately paving the way for increased access to these life-saving treatments for patients worldwide.